title: Therapy-related acute lymphoblastic leukemia with MLL rearrangement following treatment of Burkitt's leukemia.
abstract: The occurrence of therapy-related acute lymphoblastic leukemia (ALL) is rare and, to our knowledge, is not reported in patients treated for Burkitt's leukemia. We report on a child with ALL with translocation t(4;11)(q21;q23) involving the MLL gene, 13 months after chemotherapy for Burkitt's leukemia. This present observation indicates that caution should be exercised in using high cumulative doses of DNA topoisomerase II inhibitors in such patients.
authors: Service d'Oncologie Hématologique et de Thérapie Cellulaire, Universitary Hospital, Poitiers, France. f.millot@chu-poitiers.fr
authors: Frederic
authors: F
authors: Millot
authors: Francoise
authors: F
authors: Brizard
authors: Nathalie
authors: N
authors: Sorel
authors: Claude
authors: C
authors: Preudhomme
authors: Marie
authors: M
authors: Cividin
authors: Francois
authors: F
authors: Guilhot
authors: Andre
authors: A
authors: Brizard
mesh_terms: D002051:Burkitt Lymphoma / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D002648:Child; D002894:Chromosomes, Human, Pair 4; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005786:Gene Expression Regulation; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D016130:Immunophenotyping / Q000379:methods; D008297:Male; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics* / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000235:genetics* / Q000628:therapy*; D013997:Time Factors; D059005:Topoisomerase II Inhibitors; D014178:Translocation, Genetic; D016896:Treatment Outcome
chemical_list: D004791:Enzyme Inhibitors; C497422:KMT2A protein, human; D059005:Topoisomerase II Inhibitors; D051788:Myeloid-Lymphoid Leukemia Protein; D011495:Histone-Lysine N-Methyltransferase